Studies on the interaction between 1,2,3,4-tetrahydro-β-carboline and cigarette smoke: A potential mechanism of neuroprotection for Parkinson's disease

Brain Research

Volumn 802, Issue 1-2, 1998, Pages 155-162

  Soto Otero, Ramón ^a   Méndez Álvarez, Estefanía ^a   Riguera Vega, Ricardo ^a   Quiñoá Cabana, Emilio ^a   Sánchez Sellero, Inés ^a   López Rivadulla Lamas, Manuel ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

1,2,3,4 Tetrahydro carboline; Cigarette smoke; Dopaminergic neuroprotection; MAO inhibition; Parkinson's disease

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; CIGARETTE SMOKE; TRYPTOLINE; TRYPTOLINE DERIVATIVE;

ANIMAL CELL; ARTICLE; BRAIN PROTECTION; CHEMICAL COMPOSITION; CHEMICAL STRUCTURE; CHRONOLOGY; CIGARETTE SMOKING; ENZYME ACTIVITY; ENZYME INHIBITION; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ANIMALS; BRAIN; CARBOLINES; DRUG INTERACTIONS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MALE; MONOAMINE OXIDASE INHIBITORS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PLANTS, TOXIC; RATS; RATS, SPRAGUE-DAWLEY; SMOKE; SOLUTIONS; TOBACCO;

EID: 0344110532     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(98)00538-1     Document Type: Article

References (42)

1. R. Albores, E.J. Neafsey, G. Drucker, J.Z. Fields, M.A. Collins, Mitochondrial respiratory inhibition by N-methylated-β-carboline derivatives structurally resembling N-methyl-4-phenylpyridine, Proc. Natl. Acad. Sci. USA 87 (1988) 9368-9372.
2. S.A. Barker, R.E. Harrison, G.B. Brown, S.T. Christian, Gas chromatographic/mass spectrometric evidence for the identification of 1,2,3,4-tetrahydro-β-carboline as an in vivo constituent of rat brain, Biochem. Biophys. Res. Commun. 87 (1979) 146-154.
3. S.A. Barker, R.E.W. Harrison, J.A. Monti, G.B. Brown, S.T. Christian, Identification and quantification of 1,2,3,4-tetrahydro-β-carboline, 2-methyl-1,2,3,4-tetrahydro-β-carboline, and 6-methoxy-1,2,3,4-tetrahydro-β-carboline as in vivo constituents of rat brain and adrenal gland, Biochem. Pharmacol. 30 (1981) 9-17.
4. D. Ben-Shachar, R. Zuk, Y. Glinka, Dopamine neurotoxicity: inhibition of mitochondrial respiration, J. Neurochem. 64 (1995) 718-723.
5. A.A. Boulton, P.H. Yu, K.F. Tipton, Biogenic amine adducts, monoamine oxidase inhibitors, and smoking, Lancet 1 (1988) 114-115.
6. N.S. Buckholtz, W.O. Boggan, Monoamine oxidase inhibition in brain and liver produced by β-carbolines: structure-activity relationships and substrate specificity, Biochem. Pharmacol. 26 (1977) 1991-1996.
7. A.M. Cesura, A. Pleischer, The new generation of monoamine oxidase inhibitors, Prog. Drug Res. 38 (1992) 171-296.
8. 50) of an enzymatic reaction, Biochem. Pharmacol. 22 (1973) 3099-3108.
9. +, a metabolite of MPTP, by brain synaptosomes, Biochem. Biophys. Res. Commun. 128 (1985) 1228-1232.
10. + in PC12 cells: insight into potential neurotoxicants in Parkinson's disease, J. Neurochem. 62 (1994) 1503-1510.
11. M. Collins, E.J. Neafsey, K. Matsubara, β-Carbolines: metabolism and neurotoxicity, Biogenic Amines 12 (1996) 171-180.
12. +, Arch. Biochem. Biophys. 294 (1992) 539-543.
13. J.S. Fowler, N.D. Volkow, G.-J. Wang, N. Pappas, J. Logan, C. Shea, D. Alexoff, R.R. MacGregor, D.J. Schlyer, A.P. I Zezulkova, Wolf, brain monoamine oxidase A inhibition in cigarette smokers, Proc. Natl. Acad. Sci. USA 93 (1996) 14065-14069.
14. A.H. Glassman, J.E. Helzer, L.S. Covey, L.B. Cottler, F. Stetner, J.E. Tipp, J. Johnson, Smoking, smoking cessation, and major depression, J. Am. Med. Assoc. 264 (1990) 1546-1549.
15. L. Heap, R.J. Ward, C. Abiaka, D. Dexter, M. Lawlor, O. Pratt, A. Thomson, K. Shaw, T.J. Peters, The influence of brain acetaldehyde on oxidative status, dopamine metabolism and visual discrimination task, Biochem. Pharmacol. 50 (1995) 263-270.
16. R.E. Heikkila, M.V. Kindt, P.K. Sonsalla, A. Giovani, S.K. Youngster, K.A. McKeown, T.P. Singer, The importance of MAO-A in the bioactivation of neurotoxic MPTP analogs, Proc. Natl. Acad. Sci. USA 85, 6172.
17. W. Hellenbrand, A. Seidler, B.-P. Robra, P. Vieregge, W.H. Oertel, J. Joerg, P. Nischan, E. Schneider, G. ULm, Smoking and Parkinson's disease: a case-control study in Germany, Int. J. Epidemiol. 26 (1997) 328-339.
18. H. Honecker, H. Rommelspacher, Tetrahydronorharmane (tetrahydro-β-carboline), a physiological occurring compound of indole metabolism, Naunyn-Schmiedeberg's Arch. Pharmacol. 305 (1978) 135-141.
19. +), the neurotoxic metabolite of MPTP, Biochem. Biophys. Res. Commun. 148 (1987) 684-693.
20. I. Irwin I., J.W. Langston, Endogenous toxins as potential etiologic agents in Parkinson's disease, in: J.H. Ellenberg, W.C. Koller, J.W. Langston (Eds.), Etiology of Parkinson's Disease, Marcel Dekker, New York, 1995, pp. 153-180.
21. I.I. Kessler, E.C. Diamond, Epidemiologic studies of Parkinson's disease: I. Smoking and Parkinson's disease: a survey and explanatory hypothesis, Am. J. Epidemiol. 94 (1971) 16-25.
22. H. Kim, S.O. Sablin, R.R. Ramsay, Inhibition of monoamine oxidase A by β-carboline derivatives, Arch. Biochem. Biophys. 337 (1997) 137-142.
23. J.W. Langston, P. Ballard, J.W. Tetrud, Y. Irwin, Chronic parkinsonism in humans due to a product of meperidine-analog synthesis, Science 219 (1983) 979-980.
24. K. Matsubara, Occurrence of neurotoxic β-carbolinium cations in mammalian central nervous system, Biogenic Amines 12 (1996) 161-169.
25. E. Meller, E. Friedman, J.W. Schweitzer, A.J. Friedhoff, Tetrahydro-β-carbolines: specific inhibitiors of type A monoamine oxidase, J. Neurochem. 28 (1977) 995-1000.
26. E. Méndez-Álvarez, R. Soto-Otero, I. Sánchez-Sellero, M. López-Rivadulla Lamas, Inhibition of brain monoamino oxidase by adducts of 1,2,3,4-tetrahydroisoquinoline with components of cigarette smoke, Life Sci. 60 (1997) 1719-1727.
27. T. Miyake, T. Shibamoto, Quantitative analysis by gas chromatography of volatile carbonyl compounds in cigarette smoke, J. Chromatogr. A 693 (1995) 376-381.
28. D.M. Morens, A. Grandinetti, D. Reed, L.R. White, G.W. Ross, Cigarette smoking and protection for Parkinson's disease: false association or etiologic clue?, Neurology 45 (1951) 1041-1051.
29. +), Neurosci. Lett. 105 (1989) 344-349.
30. M.D. Nefzger, F.A. Quadfasel, V.C. Karl, A retrospective study of smoking in Parkinson's disease, Am. J. Epidemiol. 88 (1968) 149-158.
31. P. Peura, J.V. Johnson, R.A. Yost, K.F. Faull, Concentrations of tryptoline and meth-tryptoline in rat brain, J. Neurochem. 52 (1989) 847-852.
32. H. Rommelspacher, T. May, R. Susilo, β-Carbolines and tetrahydroisoquinolines: detection and function in mammals, Planta Med. 57 (1991) 85-92.
33. H. Sakuma, M. Kusama, S. Munakata, T. Ohsumi, S. Sugawara, The distribution of cigarette smoke components between mainstream and sidestream smoke: I. Acidic components, Beitr. Tabakforsch. Int. 12 (1983) 63-71.
34. H. Sakuma, M. Kusama, K. Yamaguchi, T. Matsuki, S. Sugawara, The distribution of cigarette smoke components between mainstream and sidestream smoke: II. Bases, Beitr. Tabakforsch. Int. 12 (1984) 199-209.
35. H. Sakuma, M. Kusama, K. Yamaguchi, S. Sugawara, The distribution of cigarette smoke components between mainstream and sidestream smoke: III. Middle and higher boiling components, Beitr. Tabakforsch. Int. 12 (1984) 251-257.
36. R. Soto-Otero, R. Riguera-Vega, E. Méndez-Álvarez, I. Sánchez-Sellero, M. López-Rivadulla Lamas, Interaction of 1,2,3,4-tetrahy-droisoquinoline with some components of cigarette smoke: potential implications for Parkinson's disease, Biochem. Biophys. Res. Commun. 222 (1996) 607-611.
37. B. Testa, R. Naylor, B. Costall, P. Jenner, C.D. Marsden, Does an endogenous methylpyridinium analogue cause Parkinson's disease?, J. Pharm. Pharmacol. 37 (1985) 679-680.
38. I. Vyas, R.E. Heikkila, W.J. Nicklas, Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: inhibition of NADH-linked substrate oxidation by its metabolite 1-methyl-4-phenylpyridinium, J. Neurochem. 46 (1986) 1501-1507.
39. J.L. Way, Cyanide intoxication and its mechanism of antagonism, Annu. Rev. Pharmacol. Toxicol. 24 (1984) 451-481.
40. M.B. Winstead, C.A. Ciccarelli, H.S. Winchell, Liberation of cyanide from α-aminonitriles relative to amygdalin, J. Pharmacol. Exp. Ther. 205 (1978) 751-756.
41. P.H. Yu, A.A. Boulton, Irreversible inhibition of monoamine oxidase by some components of cigarette smoke, Life Sci. 41 (1987) 675-682.
42. P.H. Yu, D.A. Durden, B.A. Davis, A.A. Boulton, Interaction of biogenic amines with components of cigarette smoke. Formation of cyanomethylamine derivatives, Biochem. Pharmacol. 37 (1988) 3729-3734.